• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic, IBM Watson debut hypoglycemia prediction feature for diabetes app

January 3, 2019 By Sarah Faulkner

Medtronic, IBM Watson's hypoglycemia prediction featureMedtronic (NYSE:MDT) and IBM Watson Health today launched a new feature for its Sugar.IQ personal diabetes assistant app that can predict the likelihood of a user experiencing a low glucose event within a four-hour window.

The feature, called IQcast, uses AI tech from IBM and becomes more accurate as the low blood sugar event draws nearer, according to Medtronic.

The Sugar.IQ app is available for use with Medtronic’s Guardian Connect continuous glucose monitoring system. People using the Guardian Connect CGM with the Sugar.IQ app have been able to achieve an extra 36 minutes per day in a healthy glucose range, Medtronic noted.

“Hypoglycemia, or ‘going low’, is one of the most acute and frightening events that a person living with diabetes can experience,” Dr. Lisa Latts, deputy chief health officer at IBM Watson Health, said in prepared remarks. “Fueled by the right data, AI and machine learning can play a powerful role in helping to alleviate the burden of diabetes and the worry of a hypoglycemic event, and we’ve built the new IQcast features with this goal in mind.”

“Simply put, IQcast acts like a weather forecast for people with diabetes so they can better prepare for their day,” Dr. Robert Vigersky, senior director of medical & clinical affairs for Medtronic’s diabetes unit, added.

“By predicting the likelihood of a low glucose event from anywhere between 1 and 4 hours in advance, IQcast empowers people on multiple daily injections (MDI) with insights so they can live their life with greater freedom and better health,” Vigersky said.

Medtronic and IBM Watson Health first launched the Sugar.IQ app in June last year, touting that it can evaluate how a user’s blood sugar levels respond to variables such as food intake, insulin dosing and other daily routines.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, mHealth (Mobile Health), Patient Monitoring, Wall Street Beat Tagged With: IBM Watson Health, Medtronic

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS